Q-omics provides the consensus-scored RPL7P36 profile across patient tissues and cancer cell-line models. RPL7P36 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL7P36 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPL7P36 RNA expression shows 9,594 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where RPL7P36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P36 survival associations across molecular data types. RPL7P36 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P36 RNA expression–survival associations across cancer types. High RPL7P36 expression shows unfavorable associations in KICH, UCEC, LIHC and STAD, but favorable associations in KIRC and THCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RPL7P36 RNA expression.
This table summarizes RPL7P36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P36 shows higher tumor expression in COAD, KIRP, LUSC, LIHC, LUAD and READ. The COAD box plot shows higher RPL7P36 RNA expression in tumor versus normal tissue (log2 FC = +0.141, t-test p = .002).
This table shows molecular features associated with RPL7P36 in patient tissues and cancer cell lines. In patient samples, RPL7P36 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
